Regulators in Britain on Thursday approved the first treatment derived from CRISPR, the revolutionary gene-editing method.
The manufacturers, Vertex Pharmaceuticals and CRISPR Therapeutics, say about 2,000 patients in Britain with sickle-cell disease or beta thalassemia are expected to be eligible for its treatment.
The companies anticipate that the Food and Drug Administration will approve Casgevy for sickle-cell patients in the United States in early December.
[
add
]
[
|
|
...
]